

Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F Segmented By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others), By Drug (Cytotoxic, Hormonal Therapy, Targeted Therapy, Others), By Route of Administration (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition

<https://marketpublishers.com/r/AAD09A10FC5AEN.html>

Date: February 2024

Pages: 174

Price: US\$ 4,900.00 (Single User License)

ID: AAD09A10FC5AEN

Abstracts

Global Anticancer Drug Market was valued at USD 172.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Cancer remains a formidable global health challenge, affecting millions of lives annually. In the relentless pursuit of effective treatment options, the global anticancer drug market has emerged as a critical player. This market, fueled by groundbreaking research and technological advancements, plays a pivotal role in shaping the landscape of cancer therapeutics. The global anticancer drug market has witnessed significant growth in recent years, driven by factors such as an aging population, lifestyle changes, and increased awareness of cancer. According to various market reports, the market is expected to continue its upward trajectory, reaching new heights in terms of both revenue and innovation. Immunotherapy has emerged as a game-changer in cancer treatment. Therapies such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies have gained widespread acceptance. The market is witnessing increased investment in research and

development for novel immunotherapeutic agents, aiming to enhance treatment efficacy and reduce side effects.

The era of precision medicine has brought about a paradigm shift in cancer treatment. Tailoring therapies based on a patient's genetic makeup and the molecular characteristics of their cancer has become increasingly common. This personalized approach not only improves treatment outcomes but also minimizes adverse effects. Targeted therapies continue to be a focal point in anticancer drug development. Small molecule inhibitors and monoclonal antibodies designed to target specific molecules involved in cancer growth and progression have demonstrated significant success. The market is witnessing a surge in the development of targeted therapies across various cancer types.

Key Market Drivers

Increasing Cancer Incidence is Driving the Global Anticancer Drug Market

In recent years, the global healthcare landscape has been grappling with an alarming surge in cancer incidence. This rise in cancer cases has prompted an unprecedented demand for advanced and effective anticancer drugs. As the world faces the challenges posed by the increasing prevalence of cancer, the pharmaceutical industry is stepping up its efforts to develop innovative therapies, driving the growth of the global anticancer drug market. Cancer continues to be a major public health concern, with millions of new cases diagnosed each year across the globe. The World Health Organization (WHO) estimates that cancer is the second leading cause of death worldwide, contributing to nearly 10 million deaths annually. The incidence of cancer is influenced by various factors, including lifestyle changes, environmental factors, and an aging population.

Several factors contribute to the escalating rates of cancer. Lifestyle choices such as tobacco use, unhealthy diets, lack of physical activity, and exposure to environmental carcinogens play a significant role. Additionally, an aging population, with an increased life expectancy, contributes to a higher prevalence of cancer.

Increased Investment in Research and Development is Driving the Global Anticancer Drug Market

The global anticancer drug market has witnessed significant growth in recent years, thanks to a surge in research and development (R&D) investments dedicated to combating the complex and challenging realm of cancer. As scientists delve deeper into

understanding the intricacies of cancer biology, new therapeutic approaches are emerging, leading to the development of innovative anticancer drugs. The increased investment in R&D is a driving force behind the development of novel anticancer drugs. Pharmaceutical companies are allocating substantial budgets to support groundbreaking research initiatives, enabling the exploration of diverse therapeutic avenues. This influx of funds has allowed researchers to pursue innovative strategies, including targeted therapies, immunotherapies, and precision medicine tailored to individual patient profiles. Targeted therapies have emerged as a game-changer in the field of cancer treatment. These drugs are designed to specifically target cancer cells, sparing healthy cells and minimizing side effects. The development of targeted therapies is intricately linked to the understanding of molecular and genetic abnormalities driving cancer growth. R&D investments have enabled scientists to identify and exploit these abnormalities, leading to the creation of drugs that interfere with specific cancer-promoting mechanisms.

Immunotherapy has gained prominence as a revolutionary approach to cancer treatment. By leveraging the body's immune system to recognize and destroy cancer cells, immunotherapies have shown remarkable efficacy in certain cancer types. Research investments have fueled the development of immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and cancer vaccines, providing new hope for patients with previously limited treatment options. Precision medicine represents a paradigm shift in cancer treatment, emphasizing the customization of therapies based on a patient's unique genetic and molecular profile. R&D investments have facilitated the identification of biomarkers and the development of diagnostic tools that enable oncologists to match patients with the most effective treatments. This personalized approach enhances treatment outcomes and reduces the likelihood of adverse reactions. The impact of increased R&D investments is not confined to a specific region but reverberates globally. Collaborations between academic institutions, pharmaceutical companies, and research organizations across borders are fostering a collaborative environment that accelerates progress. As a result, patients worldwide are gaining access to cutting-edge anticancer therapies, contributing to a more equitable distribution of advanced medical interventions.

Key Market Challenges

Rising Costs of Drug Development

The process of developing a new anticancer drug is lengthy, complex, and expensive. It typically begins with extensive preclinical research, where potential compounds are

tested in laboratories to assess their safety and efficacy. This phase alone requires substantial financial investment in personnel, equipment, and facilities. Following successful preclinical studies, drugs move to clinical trials, which are conducted in multiple phases involving human subjects. These trials are not only time-consuming but also expensive, with costs skyrocketing due to the need for large patient populations, extensive monitoring, and adherence to rigorous regulatory standards. According to estimates, it can take over a decade and cost billions of dollars to bring a single drug from discovery to market approval.

Stringent regulatory standards set by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) add another layer of complexity and cost to the drug development process. Meeting these standards is essential for ensuring the safety and efficacy of anticancer drugs, but the associated compliance efforts demand substantial financial resources. Moreover, as the understanding of cancer biology advances, regulatory requirements for demonstrating clinical benefit become more demanding. This evolution contributes to an increase in the size and duration of clinical trials, further elevating the overall costs of drug development. The pharmaceutical industry operates in a high-risk environment where a significant percentage of drug candidates fail at various stages of development. The risks associated with drug development, coupled with the prolonged timelines and escalating costs, can deter potential investors. This risk aversion may lead to fewer resources being allocated to anticancer drug research and development, ultimately limiting the number of new therapies entering the market.

The rising costs of drug development have a direct impact on the pricing of anticancer drugs. Pharmaceutical companies often pass on the expenses incurred during the development process to end-users, including patients, healthcare providers, and payers. As a result, the affordability of these life-saving medications becomes a concern, and access to innovative therapies may be restricted, particularly in lower-income regions.

Key Market Trends

Technological Advancements

In recent years, the field of oncology has witnessed a paradigm shift in the way cancer is diagnosed and treated, thanks to rapid advancements in technology. The global anticancer drug market is experiencing a transformative phase, with innovative technologies playing a pivotal role in shaping the future of cancer therapeutics. From

precision medicine and targeted therapies to artificial intelligence (AI) and immunotherapy, these technological breakthroughs are not only improving patient outcomes but also driving significant growth in the global anticancer drug market. One of the key drivers behind the growth of the global anticancer drug market is the advent of precision medicine and targeted therapies. Traditional chemotherapy often led to collateral damage, affecting both cancerous and healthy cells. However, precision medicine allows for a more personalized approach, taking into account the unique genetic makeup of an individual's cancer. This approach enables oncologists to prescribe drugs that specifically target the molecular and genetic abnormalities driving the growth of cancer cells.

The rise of genomics and next-generation sequencing technologies has empowered researchers to identify specific genetic mutations associated with various types of cancer. Pharmaceutical companies are increasingly developing drugs that target these specific mutations, leading to more effective and less toxic treatment options. As a result, the market for targeted anticancer therapies is expanding rapidly, providing patients with more tailored and efficient treatment regimens.

Artificial intelligence is revolutionizing drug discovery and development, significantly accelerating the identification and optimization of potential anticancer compounds. Machine learning algorithms can analyze vast datasets, including genomic information, clinical trial data, and drug interactions, to identify novel drug candidates and predict their efficacy. AI is also playing a crucial role in drug repurposing, identifying existing drugs that could be repurposed for anticancer purposes. This approach not only saves time and resources but also expedites the availability of new treatment options. The integration of AI in drug discovery is fostering innovation and efficiency in the development of anticancer drugs, contributing to the overall growth of the market.

Early and accurate diagnosis is essential for effective cancer treatment. Recent technological advancements in diagnostic imaging, liquid biopsy, and molecular diagnostics have improved the precision and speed of cancer diagnosis. Liquid biopsy, for example, allows for the detection of circulating tumor DNA in a patient's blood, providing a non-invasive method for monitoring cancer progression and treatment response. Advanced imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), offer more detailed and accurate visualization of tumors, aiding in treatment planning and monitoring.

Segmental Insights

Indication Insights

Based on the category of indication, breast cancer emerged as the dominant player in the global market for Anticancer Drug in 2023. Breast cancer remains a formidable global health challenge, affecting millions of women and, in some cases, men. The World Health Organization (WHO) estimates that breast cancer is the most common cancer among women worldwide, with over 2.2 million new cases reported in 2020 alone. The increasing prevalence of risk factors such as aging, hormonal changes, and lifestyle factors has contributed to the rising incidence of breast cancer. The dominance of breast cancer in the global anticancer drug market is a direct consequence of the disease's widespread prevalence and the continuous efforts to develop more effective and targeted therapies. Pharmaceutical companies have recognized the immense market potential and have invested heavily in research and development to bring forth innovative treatments for breast cancer patients.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics are actively involved in collaborations with pharmaceutical companies and research institutions to advance the development of novel anticancer drugs. Clinical trials conducted in hospital settings play a crucial role in evaluating the safety and efficacy of new therapies, contributing valuable data to the global anticancer drug market.

These collaborations facilitate the seamless integration of research and clinical practice, fostering an environment of innovation in cancer treatment. Patients benefit from access to cutting-edge therapies, and healthcare providers gain insights that contribute to ongoing advancements in the field.

Regional Insights

North America emerged as the dominant player in the global Anticancer Drug market in 2023, holding the largest market share in terms of value. North America, particularly the United States, has a well-established reputation for leading advancements in pharmaceutical research and development. The region hosts numerous top-tier research institutions, biotechnology companies, and pharmaceutical giants that invest significantly in developing cutting-edge anticancer drugs. The collaboration between academia, private enterprises, and government agencies has created a fertile ground for innovation, leading to the discovery of novel therapies. The United States Food and

Drug Administration (FDA) plays a pivotal role in the global pharmaceutical landscape. Its stringent yet efficient regulatory processes ensure that only safe and effective drugs enter the market. The FDA's approval is often seen as a gold standard globally, giving North American pharmaceutical companies a competitive edge. This regulatory framework has facilitated the timely approval and market launch of several groundbreaking anticancer drugs, reinforcing the region's dominance.

Key Market Players

F. Hoffmann-La Roche Ltd

Genentech, Inc.

Novartis AG

Pfizer Inc.

Bristol-Myers Squibb Company

GlaxoSmithKline plc.

Eli Lilly and Company

AstraZeneca plc

Sanofi LLC

Bayer AG

Report Scope:

In this report, the Global Anticancer Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anticancer Drug Market, By Indication:

Breast Cancer

Blood Cancer

Prostate Cancer

Gastrointestinal Cancer

Gynaecologic Cancer

Lung Cancer

Others

Anticancer Drug Market, By Drug:

Cytotoxics

Hormonal Therapy

Targeted Therapy

Others

Anticancer Drug Market, By Route of Administration:

Treatment application

Research application

Oral

Parenteral

Others

Anticancer Drug Market, By End User:

Hospitals & Clinics

Ambulatory Care Centers

Others

Anticancer Drug Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Anticancer Drug Market.

Available Customizations:

Global Anticancer Drug market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

- 1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Drug Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. GLOBAL ANTICANCER DRUG MARKET OUTLOOK

- 4.1. Market Size & Forecast
 - 4.1.1. By Value
- 4.2. Market Share & Forecast
 - 4.2.1. By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others)
 - 4.2.2. By Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others)
 - 4.2.3. By Route of Administration (Oral, Parenteral, Others)
 - 4.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
 - 4.2.5. By Region
 - 4.2.6. By Company (2023)

4.3. Market Map

- 4.3.1. By Indication
- 4.3.2. By Drug
- 4.3.3. By Route of Administration
- 4.3.4. By End User
- 4.3.5. By Region

5. ASIA PACIFIC ANTICANCER DRUG MARKET OUTLOOK

5.1. Market Size & Forecast

- 5.1.1. By Value

5.2. Market Share & Forecast

- 5.2.1. By Indication
- 5.2.2. By Drug
- 5.2.3. By Route of Administration
- 5.2.4. By End User
- 5.2.5. By Country

5.3. Asia Pacific: Country Analysis

5.3.1. China Anticancer Drug Market Outlook

- 5.3.1.1. Market Size & Forecast
 - 5.3.1.1.1. By Value
- 5.3.1.2. Market Share & Forecast
 - 5.3.1.2.1. By Indication
 - 5.3.1.2.2. By Drug
 - 5.3.1.2.3. By Route of Administration
 - 5.3.1.2.4. By End User

5.3.2. India Anticancer Drug Market Outlook

- 5.3.2.1. Market Size & Forecast
 - 5.3.2.1.1. By Value
- 5.3.2.2. Market Share & Forecast
 - 5.3.2.2.1. By Indication
 - 5.3.2.2.2. By Drug
 - 5.3.2.2.3. By Route of Administration
 - 5.3.2.2.4. By End User

5.3.3. Australia Anticancer Drug Market Outlook

- 5.3.3.1. Market Size & Forecast
 - 5.3.3.1.1. By Value
- 5.3.3.2. Market Share & Forecast
 - 5.3.3.2.1. By Indication

- 5.3.3.2.2. By Drug
- 5.3.3.2.3. By Route of Administration
- 5.3.3.2.4. By End User
- 5.3.4. Japan Anticancer Drug Market Outlook
 - 5.3.4.1. Market Size & Forecast
 - 5.3.4.1.1. By Value
 - 5.3.4.2. Market Share & Forecast
 - 5.3.4.2.1. By Indication
 - 5.3.4.2.2. By Drug
 - 5.3.4.2.3. By Route of Administration
 - 5.3.4.2.4. By End User
- 5.3.5. South Korea Anticancer Drug Market Outlook
 - 5.3.5.1. Market Size & Forecast
 - 5.3.5.1.1. By Value
 - 5.3.5.2. Market Share & Forecast
 - 5.3.5.2.1. By Indication
 - 5.3.5.2.2. By Drug
 - 5.3.5.2.3. By Route of Administration
 - 5.3.5.2.4. By End User

6. EUROPE ANTICANCER DRUG MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Indication
 - 6.2.2. By Drug
 - 6.2.3. By Route of Administration
 - 6.2.4. By End User
 - 6.2.5. By Country
- 6.3. Europe: Country Analysis
 - 6.3.1. France Anticancer Drug Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Indication
 - 6.3.1.2.2. By Drug
 - 6.3.1.2.3. By Route of Administration
 - 6.3.1.2.4. By End User

6.3.2. Germany Anticancer Drug Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Indication

6.3.2.2.2. By Drug

6.3.2.2.3. By Route of Administration

6.3.2.2.4. By End User

6.3.3. Spain Anticancer Drug Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Indication

6.3.3.2.2. By Drug

6.3.3.2.3. By Route of Administration

6.3.3.2.4. By End User

6.3.4. Italy Anticancer Drug Market Outlook

6.3.4.1. Market Size & Forecast

6.3.4.1.1. By Value

6.3.4.2. Market Share & Forecast

6.3.4.2.1. By Indication

6.3.4.2.2. By Drug

6.3.4.2.3. By Route of Administration

6.3.4.2.4. By End User

6.3.5. United Kingdom Anticancer Drug Market Outlook

6.3.5.1. Market Size & Forecast

6.3.5.1.1. By Value

6.3.5.2. Market Share & Forecast

6.3.5.2.1. By Indication

6.3.5.2.2. By Drug

6.3.5.2.3. By Route of Administration

6.3.5.2.4. By End User

7. NORTH AMERICA ANTICANCER DRUG MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Indication

- 7.2.2. By Drug
- 7.2.3. By Route of Administration
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. North America: Country Analysis
 - 7.3.1. United States Anticancer Drug Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Indication
 - 7.3.1.2.2. By Drug
 - 7.3.1.2.3. By Route of Administration
 - 7.3.1.2.4. By End User
 - 7.3.2. Mexico Anticancer Drug Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Indication
 - 7.3.2.2.2. By Drug
 - 7.3.2.2.3. By Route of Administration
 - 7.3.2.2.4. By End User
 - 7.3.3. Canada Anticancer Drug Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Indication
 - 7.3.3.2.2. By Drug
 - 7.3.3.2.3. By Route of Administration
 - 7.3.3.2.4. By End User

8. SOUTH AMERICA ANTICANCER DRUG MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Indication
 - 8.2.2. By Drug
 - 8.2.3. By Route of Administration
 - 8.2.4. By End User

8.2.5. By Country

8.3. South America: Country Analysis

8.3.1. Brazil Anticancer Drug Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Indication

8.3.1.2.2. By Drug

8.3.1.2.3. By Route of Administration

8.3.1.2.4. By End User

8.3.2. Argentina Anticancer Drug Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Indication

8.3.2.2.2. By Drug

8.3.2.2.3. By Route of Administration

8.3.2.2.4. By End User

8.3.3. Colombia Anticancer Drug Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Indication

8.3.3.2.2. By Drug

8.3.3.2.3. By Route of Administration

8.3.3.2.4. By End User

9. MIDDLE EAST AND AFRICA ANTICANCER DRUG MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Indication

9.2.2. By Drug

9.2.3. By Route of Administration

9.2.4. By End User

9.2.5. By Country

9.3. MEA: Country Analysis

9.3.1. South Africa Anticancer Drug Market Outlook

- 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Indication
 - 9.3.1.2.2. By Drug
 - 9.3.1.2.3. By Route of Administration
 - 9.3.1.2.4. By End User
- 9.3.2. Saudi Arabia Anticancer Drug Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Indication
 - 9.3.2.2.2. By Drug
 - 9.3.2.2.3. By Route of Administration
 - 9.3.2.2.4. By End User
- 9.3.3. UAE Anticancer Drug Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Indication
 - 9.3.3.2.2. By Drug
 - 9.3.3.2.3. By Route of Administration
 - 9.3.3.2.4. By End User

10. MARKET DYNAMICS

- 10.1. Drivers
- 10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

- 11.1. Recent Developments
- 11.2. Product Launches
- 11.3. Mergers & Acquisitions

12. GLOBAL ANTICANCER DRUG MARKET: SWOT ANALYSIS

13. PORTER'S FIVE FORCES ANALYSIS

- 13.1. Competition in the Drug
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Product

14. COMPETITIVE LANDSCAPE

- 14.1. F. Hoffmann-La Roche Ltd
 - 14.1.1. Company Snapshot
 - 14.1.2. Product & Services
 - 14.1.3. Financials (In case of listed)
 - 14.1.4. Recent Developments
 - 14.1.5. SWOT Analysis
- 14.2. Genentech, Inc.
- 14.3. Novartis AG
- 14.4. Pfizer Inc.
- 14.5. Bristol-Myers Squibb Company
- 14.6. GlaxoSmithKline plc.
- 14.7. Eli Lilly and Company
- 14.8. AstraZeneca plc
- 14.9. Sanofi LLC
- 14.10. Bayer AG

15. STRATEGIC RECOMMENDATIONS

16. ABOUT US & DISCLAIMER

I would like to order

Product name: Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F Segmented By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others), By Drug (Cytotoxic, Hormonal Therapy, Targeted Therapy, Others), By Route of Administration (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition

Product link: <https://marketpublishers.com/r/AAD09A10FC5AEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AAD09A10FC5AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970